1. Academic Validation
  2. Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia

Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia

  • Cancer Cell. 2018 Aug 13;34(2):271-285.e7. doi: 10.1016/j.ccell.2018.07.007.
Marlies Vanden Bempt 1 Sofie Demeyer 1 Michaël Broux 1 Jolien De Bie 1 Simon Bornschein 1 Nicole Mentens 1 Roel Vandepoel 1 Ellen Geerdens 1 Enrico Radaelli 2 Beat C Bornhauser 3 Andreas E Kulozik 4 Jules P Meijerink 5 Jean-Pierre Bourquin 3 Charles E de Bock 6 Jan Cools 7
Affiliations

Affiliations

  • 1 KU Leuven Center for Human Genetics, KU Leuven, Leuven, Belgium; VIB Center for Cancer Biology, VIB, Leuven, Belgium.
  • 2 KU Leuven Center for Human Genetics, KU Leuven, Leuven, Belgium.
  • 3 Department of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
  • 4 Department of Pediatric Hematology and Oncology, Heidelberg University Children's Hospital, Heidelberg, Germany; Hopp Children's Cancer Center at the NCT Heidelberg, Heidelberg, Germany.
  • 5 Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • 6 KU Leuven Center for Human Genetics, KU Leuven, Leuven, Belgium; VIB Center for Cancer Biology, VIB, Leuven, Belgium. Electronic address: [email protected].
  • 7 KU Leuven Center for Human Genetics, KU Leuven, Leuven, Belgium; VIB Center for Cancer Biology, VIB, Leuven, Belgium. Electronic address: [email protected].
Abstract

The NUP214-ABL1 fusion is a constitutively activated tyrosine kinase that is significantly associated with overexpression of the TLX1 and TLX3 transcription factors in T cell acute lymphoblastic leukemia (T-ALL). Here we show that NUP214-ABL1 cooperates with TLX1 in driving T-ALL development using a transgenic mouse model and human T-ALL cells. Using integrated ChIP-sequencing, ATAC-sequencing, and RNA-sequencing data, we demonstrate that TLX1 and STAT5, the downstream effector of NUP214-ABL1, co-bind poised enhancer regions, and cooperatively activate the expression of key proto-oncogenes such as MYC and BCL2. Inhibition of STAT5, downregulation of TLX1 or MYC, or interference with enhancer function through BET-inhibitor treatment leads to reduction of target gene expression and induction of leukemia cell death.

Keywords

cancer; cooperation; leukemia; mouse model; oncogenes; signaling; transcriptional regulation.

Figures
Products